NO20052557D0 - Morfolinderivater for bruk som dopamin-agonister i behandling av blant annet seksuell dysfunksjon. - Google Patents

Morfolinderivater for bruk som dopamin-agonister i behandling av blant annet seksuell dysfunksjon.

Info

Publication number: NO20052557D0
Authority: NO; Norway
Prior art keywords: treatment; inter alia; sexual dysfunction; dopamine agonists; morpholine derivatives
Prior art date: 2002-12-10

Application number

NO20052557A

Other languages

English (en)

Other versions

NO330143B1 (no

NO20052557L (no

Inventor

Charlotte Moira Norfo Allerton

David Hepworth

Andrew Simon Cook

Stephen Kwok-Fung Wong

Andrew Douglas Baxter

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-10

Filing date

2005-05-26

Publication date

2005-05-26

2002-12-10 Priority claimed from GB0228787A external-priority patent/GB0228787D0/en

2003-04-11 Priority claimed from GB0308460A external-priority patent/GB0308460D0/en

2003-06-12 Priority claimed from GB0313606A external-priority patent/GB0313606D0/en

2005-05-26 Application filed by Pfizer filed Critical Pfizer

2005-05-26 Publication of NO20052557D0 publication Critical patent/NO20052557D0/no

2005-09-06 Publication of NO20052557L publication Critical patent/NO20052557L/no

2011-02-21 Publication of NO330143B1 publication Critical patent/NO330143B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Gynecology & Obstetrics (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Addiction (AREA)
Psychology (AREA)
Anesthesiology (AREA)
Dermatology (AREA)
Hematology (AREA)
Diabetes (AREA)
Child & Adolescent Psychology (AREA)
Nutrition Science (AREA)
Pregnancy & Childbirth (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)

NO20052557A 2002-12-10 2005-05-26 Morfolinderivater, preparat inneholdende slike, slike forbindelser for anvendelse som medikament samt anvendelse av slike for fremstilling av medikament for behandling av sykdom NO330143B1 (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB0228787A GB0228787D0 (en)	2002-12-10	2002-12-10	Morpholine dopamine agonists
GB0308460A GB0308460D0 (en)	2003-04-11	2003-04-11	Morpholine dopamine agonists
GB0313606A GB0313606D0 (en)	2003-06-12	2003-06-12	Morpholine dopamine agonists
PCT/IB2003/005683 WO2004052372A1 (en)	2002-12-10	2003-12-02	Morpholine derivatives for use as dopamine agonists in the treatment of i.a. sexual dysfunction

Publications (3)

Publication Number	Publication Date
NO20052557D0 true NO20052557D0 (no)	2005-05-26
NO20052557L NO20052557L (no)	2005-09-06
NO330143B1 NO330143B1 (no)	2011-02-21

Family

ID=32512061

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20052557A NO330143B1 (no)	2002-12-10	2005-05-26	Morfolinderivater, preparat inneholdende slike, slike forbindelser for anvendelse som medikament samt anvendelse av slike for fremstilling av medikament for behandling av sykdom

Country Status (37)

Country	Link
EP (1)	EP1572214B1 (no)
JP (3)	JP3889775B2 (no)
KR (1)	KR100796102B1 (no)
AP (1)	AP2005003325A0 (no)
AR (1)	AR042339A1 (no)
AT (1)	ATE460938T1 (no)
AU (1)	AU2003302878B2 (no)
CA (1)	CA2508262C (no)
CO (1)	CO5700781A2 (no)
CR (1)	CR7869A (no)
CY (1)	CY1110130T1 (no)
DE (1)	DE60331769D1 (no)
DK (1)	DK1572214T3 (no)
EA (1)	EA009589B1 (no)
EC (1)	ECSP055850A (no)
ES (1)	ES2339767T3 (no)
GE (1)	GEP20074272B (no)
HK (1)	HK1081850A1 (no)
HN (1)	HN2003000401A (no)
HR (1)	HRP20050523A2 (no)
IS (1)	IS7843A (no)
MA (1)	MA27605A1 (no)
MX (1)	MXPA05006151A (no)
MY (1)	MY144338A (no)
NL (1)	NL1024983C2 (no)
NO (1)	NO330143B1 (no)
NZ (1)	NZ540505A (no)
OA (1)	OA13014A (no)
PA (1)	PA8591601A1 (no)
PE (1)	PE20040906A1 (no)
PL (1)	PL377480A1 (no)
PT (1)	PT1572214E (no)
RS (1)	RS51442B (no)
SI (1)	SI1572214T1 (no)
TW (1)	TW200423944A (no)
UY (1)	UY28117A1 (no)
WO (1)	WO2004052372A1 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4093588B2 (ja) *	2004-05-26	2008-06-04	ファイザー・インク	新規インダゾール及びインドロン誘導体及び調合剤としてのそれらの使用
EP1758862A1 (en) *	2004-05-27	2007-03-07	Pfizer Limited	Aminopyridine derivatives as selective dopamine d3 agonists
GB0502509D0 (en) *	2005-02-07	2005-03-16	Pfizer Ltd	Novel salt form of a dopamine agonist
TW200740779A (en)	2005-07-22	2007-11-01	Mitsubishi Pharma Corp	Intermediate compound for synthesizing pharmaceutical agent and production method thereof
GB0700786D0 (en) *	2007-01-15	2007-02-21	Pfizer Ltd	Morpholine dopamine agonists for the treatment of pain
CA2800220C (en)	2010-05-21	2019-04-30	Research Triangle Institute	Phenylmorpholines and analogues thereof
AU2011255456B2 (en)	2010-05-21	2017-01-19	Dignity Health Doing Business As St. Joseph's Hospital And Medical Center And Barrow Neurological Institute	1 - phenylmorpholine derivatives as hydroxybupropion analogues for treating drug dependence
CN105793430B (zh)	2013-12-11	2020-03-03	豪夫迈·罗氏有限公司	用于制备手性2-芳基吗啉的方法
GB2543296A (en) *	2015-10-13	2017-04-19	Indivior Uk Ltd	Dopamine D3 receptor antagonists having a morpholine moiety
EP3725768A1 (en) *	2019-04-17	2020-10-21	Newron Pharmaceuticals S.p.A.	Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives
CN118684636B (zh) *	2024-05-31	2025-03-11	上海优合贝德医药科技有限公司	一种4-吗啉-1-苯基巯基-2-丁酮的合成工艺

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB851311A (en) *	1958-04-02	1960-10-12	Geigy Ag J R	Morpholine compounds and their production
GB9108629D0 (en) *	1991-04-23	1991-06-12	Wellcome Found	Heterocyclic pharmaceutical compounds,preparation and use
GB0130219D0 (en) *	2001-12-18	2002-02-06	Pfizer Ltd	Compounds for the treatment of sexual dysfunction

2003
- 2003-12-02 MX MXPA05006151A patent/MXPA05006151A/es active IP Right Grant
- 2003-12-02 JP JP2005502342A patent/JP3889775B2/ja not_active Expired - Fee Related
- 2003-12-02 OA OA1200500171A patent/OA13014A/en unknown
- 2003-12-02 DE DE60331769T patent/DE60331769D1/de not_active Expired - Lifetime
- 2003-12-02 EA EA200500801A patent/EA009589B1/ru not_active IP Right Cessation
- 2003-12-02 AP AP2005003325A patent/AP2005003325A0/xx unknown
- 2003-12-02 ES ES03812639T patent/ES2339767T3/es not_active Expired - Lifetime
- 2003-12-02 WO PCT/IB2003/005683 patent/WO2004052372A1/en active Application Filing
- 2003-12-02 GE GEAP20038838A patent/GEP20074272B/en unknown
- 2003-12-02 RS YUP-2005/0445A patent/RS51442B/en unknown
- 2003-12-02 PT PT03812639T patent/PT1572214E/pt unknown
- 2003-12-02 KR KR1020057010474A patent/KR100796102B1/ko not_active IP Right Cessation
- 2003-12-02 PL PL377480A patent/PL377480A1/pl not_active Application Discontinuation
- 2003-12-02 AU AU2003302878A patent/AU2003302878B2/en not_active Ceased
- 2003-12-02 NZ NZ540505A patent/NZ540505A/en not_active IP Right Cessation
- 2003-12-02 CA CA002508262A patent/CA2508262C/en not_active Expired - Fee Related
- 2003-12-02 SI SI200331801T patent/SI1572214T1/sl unknown
- 2003-12-02 AT AT03812639T patent/ATE460938T1/de active
- 2003-12-02 DK DK03812639.7T patent/DK1572214T3/da active
- 2003-12-02 EP EP03812639A patent/EP1572214B1/en not_active Expired - Lifetime
- 2003-12-05 PE PE2003001234A patent/PE20040906A1/es not_active Application Discontinuation
- 2003-12-08 MY MYPI20034690A patent/MY144338A/en unknown
- 2003-12-09 TW TW092134694A patent/TW200423944A/zh unknown
- 2003-12-09 HN HN2003000401A patent/HN2003000401A/es unknown
- 2003-12-09 AR ARP030104524A patent/AR042339A1/es unknown
- 2003-12-10 PA PA20038591601A patent/PA8591601A1/es unknown
- 2003-12-10 UY UY28117A patent/UY28117A1/es not_active Application Discontinuation
- 2003-12-10 NL NL1024981A patent/NL1024983C2/nl not_active IP Right Cessation
2005
- 2005-05-12 IS IS7843A patent/IS7843A/is unknown
- 2005-05-26 NO NO20052557A patent/NO330143B1/no not_active IP Right Cessation
- 2005-06-09 HR HR20050523A patent/HRP20050523A2/hr not_active Application Discontinuation
- 2005-06-10 CR CR7869A patent/CR7869A/es unknown
- 2005-06-10 CO CO05056566A patent/CO5700781A2/es not_active Application Discontinuation
- 2005-06-10 EC EC2005005850A patent/ECSP055850A/es unknown
- 2005-06-10 MA MA28324A patent/MA27605A1/fr unknown
2006
- 2006-02-17 HK HK06102107.0A patent/HK1081850A1/xx not_active IP Right Cessation
- 2006-06-06 JP JP2006157609A patent/JP3920908B2/ja not_active Expired - Fee Related
- 2006-12-27 JP JP2006352505A patent/JP4624341B2/ja not_active Expired - Fee Related
2010
- 2010-04-26 CY CY20101100367T patent/CY1110130T1/el unknown

Also Published As

Publication number	Publication date
PT1572214E (pt)	2010-05-06
EA200500801A1 (ru)	2005-12-29
PL377480A1 (pl)	2006-02-06
MY144338A (en)	2011-08-29
JP3889775B2 (ja)	2007-03-07
AU2003302878A1 (en)	2004-06-30
RS20050445A (en)	2007-04-10
CA2508262A1 (en)	2004-06-24
OA13014A (en)	2006-11-10
SI1572214T1 (sl)	2010-07-30
GEP20074272B (en)	2007-12-25
HK1081850A1 (en)	2006-05-26
ATE460938T1 (de)	2010-04-15
IS7843A (is)	2005-05-12
NO330143B1 (no)	2011-02-21
ECSP055850A (es)	2005-09-20
NZ540505A (en)	2007-02-23
PE20040906A1 (es)	2005-01-24
HRP20050523A2 (en)	2005-08-31
AU2003302878B2 (en)	2009-04-23
JP2006511599A (ja)	2006-04-06
AR042339A1 (es)	2005-06-15
JP3920908B2 (ja)	2007-05-30
HN2003000401A (es)	2004-11-23
JP4624341B2 (ja)	2011-02-02
EP1572214B1 (en)	2010-03-17
CR7869A (es)	2005-07-08
EA009589B1 (ru)	2008-02-28
WO2004052372A1 (en)	2004-06-24
JP2006232857A (ja)	2006-09-07
MXPA05006151A (es)	2005-08-26
NL1024983C2 (nl)	2005-02-01
CO5700781A2 (es)	2006-11-30
CA2508262C (en)	2009-12-01
MA27605A1 (fr)	2005-11-01
JP2007084575A (ja)	2007-04-05
PA8591601A1 (es)	2004-12-16
NL1024983A1 (nl)	2004-06-11
DK1572214T3 (da)	2010-06-07
NO20052557L (no)	2005-09-06
ES2339767T3 (es)	2010-05-25
EP1572214A1 (en)	2005-09-14
CY1110130T1 (el)	2015-01-14
KR100796102B1 (ko)	2008-01-21
DE60331769D1 (de)	2010-04-29
AP2005003325A0 (en)	2005-06-30
KR20050094813A (ko)	2005-09-28
TW200423944A (en)	2004-11-16
UY28117A1 (es)	2004-07-30
RS51442B (en)	2011-04-30

Publication	Publication Date	Title
HK1081850A1 (en)	2006-05-26	Morpholine derivatives for use as dopamine agonists in the treatment of i.a. sexual dysfunction
NO20053215D0 (no)	2005-06-30	Pyrazolderivater med anvendelse som COX-1-inhibitorer.
NO20053775D0 (no)	2005-08-08	Diazepinoindol derivater som kinaseinhibitorer.
IS7840A (is)	2005-05-09	3-(3,5-díoxó-4,5-díhýdró-3H-(1,2,4)tríasín-2-ýl)-bensamíð afleiður sem P2X7-hindrar til notkunar í meðferð á bólguvaldandi sjúkdómum
DE502004002801D1 (de)	2007-03-15	Bohrlochbehandlungsmittel, enthaltend ethercarbonsäuren
NO20091395L (no)	2009-04-06	Nye tiofenderivater
NO20082793L (no)	2008-06-20	Nye tiofenderivater
HK1093503A1 (en)	2007-03-02	Pyrido 2, 1-a-isoquinoline derivatives as ddp-IV inhibitors
ECSP045081A (es)	2004-06-28	Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
NO20052887D0 (no)	2005-06-14	Pyridazinonderivater som GSK-3Beta inhibitorer.
IS7738A (is)	2005-03-10	Þíasól efnasambönd til notkunar í meðferð á taugahrörnunar truflunum.
NO20053356L (no)	2005-07-11	Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
NO20052993D0 (no)	2005-06-17	4,5-diaryltiazolderivater som CB-1 ligander.
EA200501928A1 (ru)	2006-12-29	Пирролодигидроизохинолины как ингибиторы pde10
HRP20090017T3 (en)	2009-03-31	3,11b-cis-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammation
CL2007002384A1 (es)	2008-01-18	Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
PL377864A1 (pl)	2006-02-20	Pochodne 1-N-(fenylo)-2-N-(fenylo)pirazolidyno-1,2-dikarboksyamidowe jako inhibitory czynnika koagulacyjnego Xa do leczenia zakrzepic
CL2007002380A1 (es)	2008-01-18	Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
AU2003250475A8 (en)	2004-02-25	5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors
NO20024364D0 (no)	2002-09-12	Anvendelse av pyrido [3,2-E]-pyrazinoner som inhibitorer av fosfodiesterase 5 for behandling av erektil dysfunksjon
DK1511718T3 (da)	2009-06-22	N-acylaminobenzenderivater som selektive monoaminoxidase B-inhibitorer
WO2005032490A3 (en)	2005-07-28	Cyclic diamines and derivatives as factor xa inhibitors
NO20055098D0 (no)	2005-11-01	Anvendelse av 10-hydroksy-10,11-dihydrokarbamazepinderivater for behandling av affektive forstyrrelser
NO20032304L (no)	2003-07-15	Anvendelse av selektive dopamin D4-reseptoragonister for behandling av seksuell dysfunksjon
ATE325115T1 (de)	2006-06-15	Pyrimidinderivate als selektive cox-2-inhibitoren

Legal Events

Date	Code	Title	Description
2012-07-23	MM1K	Lapsed by not paying the annual fees